Phase 2
Completed N=223
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
epithelial ovarian cancer · Fallopian tube cancer · Peritoneal Cancer
Source: ClinicalTrials.gov NCT01447706 ↗
Enrolled (actual)
223
Serious AEs
38.2%
Results posted
May 2016
Primary outcomePrimary: Progression Free Survival — 3.75; 3.68 months
Summary
To determine whether the combination of MM-121 plus paclitaxel is more effective than paclitaxel alone
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Progression Free Survival |
3.75; 3.68 | — |
| SECONDARY Overall Survival |
13.70; 10.12 | — |
Eligibility Criteria
Inclusion Criteria
- Locally advanced/metastatic or recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer
- Received at least one prior platinum based chemotherapy regimen
- Platinum-resistant or refractory
- Eligible for weekly paclitaxel
- Adequate liver and kidney function
- 18 years of age or above
Exclusion Criteria
- Evidence of any other active malignancy
- History of severe allergic reactions to paclitaxel or other drugs formulated in Cremophor®EL
Data sourced from ClinicalTrials.gov (NCT01447706). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.